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Abstract. Subtraction hybridization applied to a ‘differentiation
therapy’ model of cancer employing human melanoma cells
resulted in the cloning of melanoma differentiation associated
gene-7/interleukin-24 (mda-7/IL-24). Initial studies confirm an
inverse correlation between mda-7 expression and melanoma
development and progression. Forced expression of mda-7 by
means of a plasmid or via a replication incompetent adeno-
virus (Ad.mda-7) promotes growth suppression and induces
apoptosis in a broad array of human cancers. In contrast,
mda-7 does not induce growth suppressive or toxic effects in
normal cells. Based on structure (containing an IL-10 signature
motif), secretion by cells (including subsets of T-cells) and
location on chromosome 1q (in an area containing IL-10-
family genes), mda-7 has now been renamed mda-7/IL-24.
Studies by several laboratories have uncovered many of mda-7/
IL-24's unique properties, including cancer-specific apoptosis-
induction, cell cycle regulation, an ability to inhibit angio-
genesis, potent ‘bystander antitumor activity’ and a capacity
to enhance the sensitivity of tumor cells to radiation, chemo-
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therapy and monoclonal antibody therapy. Moreover, based on
its profound cancer tropism, substantiated by in vivo human
xenograft studies in nude mice, mda-7/IL-24 (administered as
Ad.mda-7) was evaluated in a phase I clinical trial in patients
with melanomas and solid cancers. These studies document
that mda-7/IL-24 is well tolerated and demonstrates evidence
of significant clinical activity. In these contexts, mda-7/IL-24
represents a unique cytokine gene with potential for therapy
of human cancers. The present review focuses on three unique
properties of mda-7/IL-24, namely its potent ‘bystander anti-
tumor activity’, ability to sensitize tumor cells to radiation, and
its antiangiogenesis properties. Additionally, an overview of
the phase I clinical trial is provided. These studies affirm that
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1. Introduction
A novel melanoma differentiation associated (mda) gene,
mda-7, was identified with a subtraction hybridization protocol
(1) using temporally-spaced cDNA libraries isolated from
terminally differentiated human melanoma cells treated with
ß-interferon and the protein kinase C activator mezerein (2).
The mda-7 cDNA encodes a 24-kDa protein, which contains
an interleukin (IL)-10 signature motif at amino acids 101-121
(SDAESCYLVHTLLEFYLKTVF) shared by other members
of the IL-10 family of cytokines (3,4). Based on sequence
homology, chromosomal localization, and its functional
properties, the mda-7 gene is now classified as a member of
the IL-10 family of cytokines and named IL-24 (4-8). The
MDA-7/IL-24 protein contains a consensus signal sequence
and a proteolytic cleavage site permitting secretion from
cells. Expression of MDA-7/IL-24 protein in normal cells is
restricted to cells of the immune system and melanocytes
(5,7,9). MDA-7/IL-24 expression is decreased during patho-
logic progression of melanocytes to melanomas as demon-
strated by both RT-PCR (2) and immunohistochemistry (10).
This correlation between the loss of gene expression and
tumor invasion suggests that mda-7/IL-24 might function as a
tumor suppressor (2,11,12). Further studies in vitro indicated
that the functional antitumor attributes of mda-7/IL-24 were
dependent on MDA-7/IL-24 expression level (13). When
present at low physiological levels, mda-7/IL-24 exhibited
specific immunostimulatory properties (see details below).
However, when this gene was overexpressed in diverse cancer
cells in vitro by transfection with a mda-7/IL-24 cDNA or by
adenoviral infection with a recombinant replication incompetent
adenovirus, Ad.mda-7, it displayed potent tumor killing and
apoptosis-inducing properties (reviewed in refs. 4,6,8,14-20).
Infection with Ad.mda-7 results in apoptosis induction
and cell death in a wide variety of solid tumors including
melanoma, malignant glioma, fibrosarcoma and carcinomas of
the breast, cervix, colorectum, liver, lung, ovary and prostate.
The tumor suppressing ability of mda-7/IL-24 is now well
established and is independent of the status of other tumor
suppressor genes, such as p53 and Rb, or apoptosis regulating
genes, such as bax or caspases, in tumor cells (12,21-25). A
provocative discovery was that overexpression of mda-7/
IL-24 in normal cells, such as normal human epithelial cells,
melanocytes, astrocytes or fibroblasts, did not affect their
growth or viability. This in vitro tumor-selective cytotoxicity
was confirmed by in vivo experiments in animal models
containing human breast, lung and colorectal carcinomas and
in glioma xenografts (23-26). Based on the results obtained
using in vitro studies and in in vivo preclinical animal
modeling, mda-7/IL-24 emerged as a promising new and
potentially widely applicable antitumor therapeutic agent,
possessing direct tumor growth inhibitory effects as well as
‘bystander antitumor’ properties. Findings from a completed
phase I dose-escalation trial on 22 advanced cancer patients
who received intratumoral injection of a non-replicating adeno-
virus vector carrying the mda-7/IL-24 transgene (INGN 241)
were recently reviewed (6,17,18,27-29). These results confirm
that the clinical activities of INGN 241 (Ad.mda-7) include
apoptotic and antitumor activities and systemic immune
activation and can generate both direct tumor growth inhibition
and ‘bystander antitumor’ effects.
2. Mechanisms of antiapoptotic properties of mda-7/IL-24
IL-20/IL-22 receptor independence. Within the IL-10 family,
IL-19, IL-20 and IL-24 exhibit substantial sharing of receptor
complexes; all three are capable of signaling through IL-20R1/
IL-20R2, and both IL-20 and IL-24 can also use IL-22R1/
IL-20R2 (30). Nevertheless, the biological activities of these
three cytokines appear quite distinct; since only mda-7/IL-24
induces tumor-specific apoptosis, and this effect can be
receptor-independent (31). The MDA-7/IL-24 protein binds to
IL-20 and IL-22 receptor complexes resulting in JAK/STAT
activation (30,32,33). However, treatment with tyrosine kinase-
specific inhibitors (Genistein and AG18) or a JAK-selective
inhibitor (AG490) does not alter Ad.mda-7-induced apoptosis
in diverse cancer cell lines (31). In addition, there is no
correlation between the pattern of expression of IL-20R1,
IL-20R2, and IL-22R mRNA and susceptibility to Ad.mda-7-
induced cell death in different cell lines. Therefore, signaling
events leading to Ad.mda-7-induced apoptosis might be
tyrosine kinase independent and can be distinguished from
mda-7/IL-24 cytokine function-related properties mediated
by the IL-20/IL-22 receptor complexes that require JAK/STAT
kinase activity (31,34,35).
Mitochondrial pathway and reactive oxygen species (ROS)
production. In vitro studies were performed to address
the mechanism(s) by which overexpression of mda-7/IL-24
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induces death selectively in cancer cells. Despite these
efforts, the precise pathways of mda-7/IL-24-induced apoptosis
remain to be defined. Evidences from earlier studies suggested
an involvement of the intrinsic/mitochondrial pathway of
apoptosis. Transfection of breast carcinoma cells with an
mda-7/IL-24 cDNA led to proapoptotic Bax up-regulation
and subsequent apoptosis induction (25,36). The onset of
apoptosis was blocked by antiapoptotic Bcl-2 overexpression.
Further studies in melanoma (12), glioblastoma multiforme
(26,37,38), renal carcinoma (39) and prostate carcinomas
(21,40,41) confirmed the involvement of the Bcl-family of
proteins in mda-7/IL-24-induced apoptosis. In most tumor
cell contexts, overexpression of MDA-7/IL-24 protein leads
to the significant down-regulation of antiapoptotic (Bcl-2 and
Bcl-xL) and/or to the up-regulation of proapoptotic (Bax and
Bak) members of the Bcl-family. It should be noted that
Ad.mda-7 can induce apoptosis in bax-null DU-145 prostate
cancer cells (21); therefore, apoptosis can be mediated by a
bax-independent pathway. Moreover, overexpression of anti-
apoptotic Bcl-family members differentially protects prostate
cancer cells from the mda-7-induced apoptosis (21). Bcl-xL
overexpression prevents Ad.mda-7-induced apoptosis in
DU-145 and PC-3 prostate carcinoma cells, while Bcl-2 over-
expression protects LNCaP cells from mda-7/IL-24-induced
apoptosis. The reasons for this disparity are not understood
and are currently being investigated.
Detailed studies in prostate cancer cells identify reactive
oxygen species (ROS) as an active component in mda-7/IL-24-
induced apoptosis (Fig. 1) (39,42,43). When overexpressed
inside a cancer cell MDA-7/IL-24 protein directly or indirectly
affects mitochondria, causing mitochondrial dysfunction and
the inner mitochondria membrane potential to drop thereby
leading to ROS production and to apoptosis induction. All
of the changes described above are absent after Ad.mda-7
infection of normal prostate epithelial cells. Antioxidants (N-
acetyl-L-cysteine and Tiron) and inhibitors of mitochondrial
permeability transition (cyclosporine A and bongkrekic
acid) inhibit Ad.mda-7-induced mitochondrial dysfunction
and apoptosis in prostate cancer cells. Conversely, agents
augmenting ROS production (arsenic trioxide, NSC656240,
and PK11195) facilitate Ad.mda-7-induced apoptosis. Ectopic
expression of Bcl-2 and Bcl-xL inhibits mitochondrial changes,
ROS production, and apoptosis providing additional support
for an association between mitochondrial dysfunction and
Ad.mda-7 action. These studies present definitive evidence
that changes in mitochondrial function and ROS production
represent key components associated with selective killing of
prostate cancer cells by mda-7/IL-24.
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Figure 1. Model of mda-7/IL-24-induced apoptosis in cancer cells. Outline of proposed physiologic (left) and ectopic (right) effects of mda-7/IL-24 on normal
and cancer cells. When normally or ectopically overexpressed, MDA-7/IL-24 localizes to the ER/Golgi compartments, whether or not the protein contains a
secretory signal. Accumulation of MDA-7/IL-24 protein in this compartment triggers apoptosis that could involve induction of ER stress and/or reactive
oxygen species in mitochondria. Secreted MDA-7/IL-24 protein employs the IL-20/IL-22 receptors to activate signal transduction pathways and/or potentially
enter cancer cells and activate proapoptotic pathways by localization and accumulation in the ER/Golgi compartment and/or by inducing mitochondrial
dysfunction. A combination of pathways triggered by mda-7/IL-24 results in transformed cell-specific apoptosis. Modified from Lebedeva et al (17).
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The ability of MDA-7/IL-24 to produce ROS may prove
extremely important for treatment of pancreatic cancer.
Pancreatic cancer cells are resistant to mda-7/IL-24-induced
apoptosis due to a diminished capacity to convert mda-7/IL-24
mRNA into protein (44). This translational block can be
reversed by combinational treatment with Ad.mda-7/IL-24
and agents that increase the ROS levels within cells, such as
arsenic trioxide, N-(4-hydroxyphenyl) retinamide, or dithio-
phene (42). Induction of apoptosis in vitro and suppression of
tumorigenesis in vivo in nude mice are induced in pancreatic
cancers independently of their K-ras status upon combinatorial
treatment with Ad.mda-7/IL-24 and a ROS-inducing agent.
ROS inhibitors, including N-acetyl-cysteine and Tyron,
block this effect.
ER-stress and its link to mitochondria. In addition to
modification of mitochondrial function, mda-7/IL-24 has
also been shown to kill cancer cells by causing endoplasmic
reticulum (ER) stress (45-47). ER stress may be caused by
misfolded protein accumulation followed by the activation of
a highly conserved unfolded protein response (UPR). These
events lead to apoptosis through the induction of growth arrest
and DNA-damage-inducible (GADD) genes (48,49). The
hypothesis of a role for mda-7/IL-24-induced ER stress and
cancer cell apoptosis is supported by the fact that mda-7/IL-24
induces GADD genes and further activates p38MAPK in the
context of transformed cells (46,50).
Previous studies document that signaling events leading
to Ad.mda-7-induced transformed cell apoptosis are tyrosine
kinase-independent (31). These results suggest that mda-7/
IL-24 cancer cell-specific activity can occur through mecha-
nisms independent of binding to its currently recognized
cognate receptors and might even occur independent of
receptor function. An adenovirus vector expressing a non-
secreted version of MDA-7/IL-24 protein was generated by
deletion of its signal peptide (45). This non-secreted protein
was as effective as wild-type secreted MDA-7/IL-24 in
inducing apoptosis in prostate carcinoma cell lines and dis-
played transformed cell specificity and localization of MDA-7/
IL-24 in the Golgi/ER compartments. These results indicate
that mda-7/IL-24-mediated apoptosis can be triggered through
a combination of intracellular as well as secretory mechanisms
and could occur efficiently in the absence of protein secretion.
Treatment of susceptible prostate cancer cell lines with
Ad.mda-7 as well as Ad.SP-mda-7 induces killing to a com-
parable extent through ERK1/2-dependent and JAK/STAT-
independent pathways (45). The fact that both secreted and
non-secreted forms of MDA-7/IL-24 protein have comparable
apoptosis-inducing activity was unanticipated, adding an
additional level of complexity in understanding how this
novel molecule works. Localization of full-length MDA-7/
IL-24 protein in the ER/Golgi compartments is consistent
with the signal peptide hypothesis (51) and the currently
known and predicted secreted cytokine nature of the protein
(6,14). Because the signal-peptideless mutant of MDA-7/IL-24
protein does not contain an export signal, it is predicted to
remain in the cytosol. We have, however, confirmed through
confocal immunofluorescence studies that a significant fraction
of this protein is able to enter the ER and Golgi apparatus
and that proteins derived from wild-type and mutant viruses
appear to have overlapping patterns of localization within the
cell (45). It is not possible to rule out cryptic internalization
signals that become active in the absence of the actual signal
peptide, as the identity of these cryptic sites is currently
hypothetical. Western blot analyses performed on protein-
derived cytosolic and extracellular fractions of cells infected
with both viruses indicated that only full-length MDA-7/IL-24
was processed and secreted. It is also possible that adenovirus
infection produced relatively large amounts of protein that even
in the absence of a specific targeting sequence possesses the
ability to cross membranes and accumulate in the ER/Golgi
because of charge and/or tertiary structure. However, because
localization of MDA-7/IL-24 is similar in both normal (P69)
and cancer (DU-145) cells, differences in cellular localization
of this protein can be excluded as a direct mechanism under-
lying the differential apoptosis-inducing activity of MDA-7/
IL-24 toward cancer cells. There are two possible explanations
of differential MDA-7/IL-24-induced killing in tumor and
normal cells. One is that enhanced sensitivity may be due to
the ‘activated’ or ‘destabilized’ nature of tumor compared to
normal cells, which enhances cell death after the ER-stress
response is triggered. The other possibility is that mda-7/IL-24
not only induces the classical ER-stress response that favors
apoptosis, but it also induces additional specific pathways
that cause apoptosis only in transformed cell lines. We demon-
strated that mda-7/IL-24 localizes to the ER compartment
both in normal and cancer cells and is therefore in a position
to induce this pathway irrespective of the transformation status
of the cell (45). Current data provide some support for both
hypotheses, however additional studies are required. GADD
family gene induction as well as p38 MAPK activation is
induced only in transformed and not in normal cells (46,50)
indicating that the disparate response might be due to
differential activation, either in strength or in duration of the
ER-stress response. However, this does not rule out the
activation of additional pathways, specifically in cancer cells.
In a microarray-based study, mda-7/IL-24 was shown to induce
expression of ER-stress response genes such as BiP/GRP78,
PP2A, HSJ1 and TRA1 in H1299 lung carcinoma cells (52).
Nevertheless, with the exception of BiP/GRP78, which is
selectively up-regulated in cancer cells (46), no comparative
data for most of these genes is available contrasting normal
and cancer cells.
MDA-7/IL-24 modulates multiple apoptotic signaling path-
ways. Expanding studies in diverse systems reveal that the
signal transduction pathways mediating mda-7/IL-24-induced
apoptosis are varied and multiple signaling pathways are
activated in different tumor cell lines upon Ad.mda-7 infection
or treatment with recombinant GST-MDA-7 protein (53)
(summarized in Fig. 2). Experiments in melanoma cell lines
demonstrated that SB203580, a specific inhibitor of p38
MAPK pathway, protects these cells from Ad.mda-7-induced
apoptosis. Ad.mda-7 infection resulted in phosphorylation of
p38 MAPK and induction of the GADD family of genes in
melanoma cells, but not in normal melanocytes (50). In general,
overexpression of each GADD gene from the family in
combination (GADD34, GADD45α, GADD45ß, GADD45γ
and GADD153) led to synergistic or cooperative antiprolifer-
ative effects (54). Ad.mda-7 infection resulted in significant
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induction of GADD153, GADD45α and GADD34, and a
moderate induction of GADD45γ (50). Both inhibition of the
p38 MAPK pathway (either pharmacologically with SB203580
or by an adenovirus expressing a dominant negative p38
MAPK) and inhibition of the GADD family of genes by an
antisense approach rescued melanoma cells from Ad.mda-7-
induced apoptosis. Activation of the p38 MAPK pathway
followed by induction of the GADD family of genes also plays
a crucial role in Ad.mda-7-modulated apoptosis in glioblastoma
multiforme (37), prostate cancer (31,41,46), and breast cancer
cells (unpublished data).
Paradoxically, p38 MAPK phosphorylation by MDA-7/
IL-24 in chronic lymphocytic leukemia (CLL)-B-cells promoted
survival of these malignant cells (55). Both mda-7/IL-24
mRNA and protein were overexpressed in the CLL B-cells
examined, and p38 MAPK, a downstream mda-7/IL-24
signaling target, was highly phosphorylated in all CLL cells,
but not in normal B-cells. Obviously, phospho-p38 MAPK
has no proapoptotic functions in CLL cells and may instead
be required for survival, as suggested from these studies.
Correspondingly, phosphorylation of p38 MAPK following
transfection of CLL cells with mda-7/IL-24 promoted CLL
cell survival (55). These studies do not exclude the possibility
of mda-7/IL-24 signaling through a p38 MAPK-independent
mechanism; however, their data suggest a competition
between mda-7/IL-24 and SB203580 (a specific inhibitor of
p38 MAPK) for p38 MAPK activation.
In non-small cell lung carcinoma (NSCLC) cells, Ad.mda-7
induced apoptosis via up-regulation of double stranded RNA-
dependent protein kinase (PKR). Infection with Ad.mda-7
led to the phosphorylation of PKR and also its downstream
targets eIF2α, Tyk2, Stat1, Stat3, and p38 MAPK (56,57).
Ad.mda-7 treatment activated caspases 3, 8 and 9 and cleavage
of Bid and PARP in NSCLC cells. The activation of PKR
appeared to be upstream of caspase activation because pre-
treatment with caspase inhibitors failed to prevent PKR
phosphorylation. Treatment with a specific serine/threonine
kinase inhibitor 2-aminopurine blocked Ad.mda-7-induced
apoptosis and also activation of PKR and eIF2α (56). A recent
study by Chada et al (58) reported PKR up-regulation in
breast cancer cell lines upon Ad.mda-7 infection. Further
investigation of the interaction between MDA-7/IL-24 and
PKR in NSCLC cells suggested a role for posttranslational
regulation of PKR by MDA-7/IL-24 (59). A physical inter-
action of MDA-7/IL-24 and PKR was confirmed by immuno-
fluorescence and coimmunoprecipitation studies. In both
studies (56,59), the authors indicate an inability of Ad.mda-7
to induce apoptosis in PKR null (-/-) mouse embryonic
fibroblasts (MEF), but not in PKR wild-type MEFs, providing
additional proof of PKR involvement in Ad.mda-7-modulated
apoptosis. Nevertheless, this finding requires further in-
dependent confirmation given that Ad.mda-7 does not
induce apoptosis in a wide array of normal human or rodent
cells.
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Figure 2. Signaling pathways involved in mda-7/IL-24 activity in cancer cells, endothelial cells and immune system cells. Overview of the signaling pathways
associated with Ad.mda-7 and MDA-7/IL-24 activity in cancer cells and in the immune system. Modified from Sauane et al (45).
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Activation of p38 MAPK following Ad.mda-7 infection
appears to be a common event linking the PKR and p38 MAPK
pathways (50,56,57). It is possible that in melanoma cells p38
MAPK activation is downstream of PKR activation, although
in melanoma cells the post-p38 signal transduction changes
seem to be more important in Ad.mda-7-induced apoptosis.
Since eIF2α phosphorylation activates the transcription factor
ATF4, which in turn activates GADD153 (60), there is a
significant level of cross talk between the PKR and the p38
MAPK signal transduction pathways. Additional studies are
required to identify the upstream molecules within PKR and
p38 MAPK pathways involved in Ad.mda-7-induced apoptosis.
The c-Jun NH2-terminal kinase (JNK) pathway is another
important signaling pathway involved in mda-7/IL-24-induced
apoptosis. Infection with Ad.mda-7 radiosensitizes malignant
glioma (37,61) and prostate cancer cells (40). A combination
of Ad.mda-7 and γ-irradiation activates JNK in glioma and
prostate cancer cells, and treatment with a specific JNK
inhibitor, SP600125, prevents apoptosis after the combination
treatment (40,61). JNK activation leads to down-regulation
of antiapoptotic Bcl-xL and/or Bcl-2 in glioma and prostate
carcinoma cells (38,40) and to the up-regulation of proapoptotic
Bax and Bak proteins in prostate carcinoma cells (40).
Blocking of JNK phosphorylation with SP600125 abrogates
these changes in the levels of Bcl-family proteins. In NSCLC
cells, curcumin (dietary pigment that inhibits JNK activation)
prevents phosphorylation of c-jun and radiosensitization by
Ad.mda-7 (62).
A potential negative regulation of ß-catenin and PI3K/Akt
signaling pathways, which are implicated in cell-cell adhesion,
cytoskeletal rearrangements, and membrane trafficking in
breast and lung cancer cells, by MDA-7/IL-24 was reported
(63). Using microarray analysis, increased protein expression
was evident from tumor suppressor genes such as E-cadherin,
APC, GSK-3ß, and PTEN after Ad.mda-7 infection. At the
same time, expression of proto-oncogenes involved in ß-catenin
and PI3K signaling was decreased. Ad.mda-7 treatment led
to a redistribution of cellular ß-catenin from the nucleus to
the plasma membrane. As a result, LEF/TCF transactivation
was significantly reduced, and E-cadherin-ß-catenin adhesion
complex was up-regulated in a tumor cell-specific manner.
Furthermore, Ad.mda-7 infection of breast and lung cancer
cells down-regulated the expression of PI3K pathway members
(p85 PI3K, FAK, ILK-1, Akt, and PLC-γ). Experiments did
not indicate if overexpression of ß-catenin or activation of the
PI3K pathway protects these cells from Ad.mda-7-induced
apoptosis. In conclusion, Ad.mda-7 appears to negatively
regulate both the PI3K and the ß-catenin signaling pathways
in breast and lung cancer cells resulting in restoration of
apoptosis induction. Moreover, PI3K activation has been
implicated in chemoresistance and radioresistance in tumor
cells; thus, Ad.mda-7 treatment should serve as a chemo- and
radiosensitizer. Ad.mda-7 regulates multiple members of the
ß-catenin and PI3K pathways that are considerably redundant
and simultaneously produce antiproliferative, proapoptotic,
and antimetastatic phenotypes. Although it is not clear where
these changes are initiated, mda-7/IL-24 appears to act up-
stream of PI3K, PLC-γ, and PTEN. It is significant that the
ß-catenin and PI3K pathways were not altered by mda-7/IL-24
expression in normal HUVEC cells.
Activation of the Fas-FasL signaling pathway occured in
the human ovarian cancer cell line MDAH 2774 following
infection with Ad.mda-7, where Ad.mda-7 significantly
inhibited cell proliferation and induced apoptosis. Early mda-7/
IL-24-induced activation of the transcription factors c-Jun
and activating transcription factor 2 (ATF2), which stimulated
the transcription of an immediate downstream target, the
death-inducer Fas ligand (FasL), and its cognate receptor
Fas. The activation of NF-κB and induction of Fas-associated
factor 1, FADD, and caspase-8 were associated with the
activation of Fas-FasL (64). However, another study by Emdad
et al (65) reported p38 MAPK activation upon adenovirus-
mediated mda-7 infection in several ovarian cancer cell lines.
The level of phosphorylated p38 MAPK correlated with the
killing effect of mda-7/IL-24 in these cells, and SB203580
(selective p38 MAPK inhibitor) significantly abolished this
killing effect. Thus, activation of p38 MAPK presents a more
general effect than induction of the Fas-FasL pathway and
might be a key element in mda-7/IL-24-induced apoptosis in
ovarian carcinoma cell lines as well as in other cancer cell
lines (46,50,61,65).
3. mda-7/IL-24 expression radiosensitizes cancer cells
Radiotherapy is a common option for cancer therapy;
however, because of high toxicity at therapeutic doses the
efficiency of this treatment is often suboptimal. Ionizing
radiation (IR) generates hydroxyl radicals in water that can
impact the function of mitochondria in cells, resulting in
amplification of the amount of reactive oxygen and nitrogen
species (66,67). In studies using human malignant glioma
(26,37,38,61) and prostate carcinoma (40), the ability of both
IR and mda-7/IL-24 to generate ROS was directly linked to
the radiosensitizing properties of this gene. Additional studies
in ovarian carcinoma (65), NSCLC (23,62) and breast cancer
cells (58) confirmed the radiosensitizing ability of mda-7/IL-24
gene. Studies in vitro highlighted the importance of JNK
activation as a mediator of radiosensitization effect and its
p53 independence (6,26,37,38,40,61,62).
In glioma cells, the antiproliferative effects of Ad.mda-7
were enhanced by IR in a greater than additive manner (37).
The radiosensitizing effects were not observed in non-trans-
formed primary human fetal astrocytes. Growth inhibition of
glioma cells in vitro correlated with an increased number of
cells in the G1/G0 and G2/M phases of the cell cycle, confirming
cell cycle independence of the radiosensitization effect
(61). Irradiation of cells, but not Ad.mda-7 infection itself,
dramatically enhanced JNK 1/2 activity. Accordingly,
inhibition of JNK 1/2 with its specific inhibitor SP600125
abolished radiosensitization properties of MDA-7/IL-24.
Both Ad.mda-7 and recombinant GST-MDA-7/IL-24 protein
demonstrated radiosensitizing properties in malignant glioma
cell lines, and this effect correlated with increased expression
of specific members of the GADD gene family, particularly,
GADD153 (37). Similarly, antiproliferative and cytotoxic
properties of recombinant GST-MDA-7/IL-24 protein were
enhanced by radiation in primary (non-established) human
glioma cells (38). In vivo, Ad.mda-7 enhanced the survival of
Fischer 344 rats implanted intracranially with rat malignant
glioma cells. Radiation did not alter survival in control-infected
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animals, whereas it prolonged survival in animals infected
with Ad.mda-7 (26).
GST-MDA-7/IL-24 protein also demonstrated radio-
sensitizing effect in vitro in breast cancer cells MDA-MB-231
(53). Moreover, ectopic mda-7/IL-24 expression (or treatment
with purified recombinant GST-MDA-7/IL-24 protein) in
combination with IR was able to overcome both radioresistance
and de novo resistance to mda-7/IL-24-induced apoptosis in
prostate cancer cells overexpressing Bcl-2/Bcl-xL (40). JNK
activation was documented to be a central event in the radio-
sensitization of cancer cells and blocking of JNK activation
ameliorated this radiation enhancement effect (40). Considering
the fact that elevated expression of Bcl-xL and Bcl-2 are
frequent events in prostate cancer development and progression,
the results of this study support the use of IR in combination
with mda-7/IL-24 to augment the therapeutic benefit of this
gene in prostate cancer, particularly in the context of tumors
displaying resistance to radiation therapy owing to Bcl-2
family members overexpression.
In NSCLC, Ad.mda-7 infection enhanced radiosensitivity
independently of the p53 status of the cells and independently
of any ability to up-regulate the expression of Fas or BAX.
Phosphorylated c-Jun expression was demonstrated in NSCLC
cell lines treated with both IR and Ad.mda-7, but not in
normal human lung fibroblasts, CCD-16 (62). Nishikawa et al
(23) demonstrated that not only did Ad.mda-7 infection in
combination with radiation enhance apoptosis in tumors,
but also that secreted MDA-7/IL-24 protein sensitized
HUVEC cells to IR thus inhibiting angiogenesis. Further
studies revealed that Ad.mda-7 sensitizes NSCLC cells to IR
by suppressing the activity of non-homologous end-joining
pathway of double strand break repair (68). A recent study
by Chada et al (58) described a synergistic effect of the
combination of Ad.mda-7 and IR on breast cancer cells in vitro
and in vivo, however, the mechanism of this effect was not
investigated.
Emdad et al (65) demonstrated that mda-7/IL-24-induced
apoptosis in ovarian cancer cells could be significantly
enhanced by combination with ionizing radiation. Additionally,
mda-7/IL-24 gene delivery under the control of a minimal
promoter region of progression elevated gene-3 (PEG-3),
which functions selectively in diverse cancer cells with
minimal activity in normal cells (69-74), displayed a selective
radiosensitizing effect in ovarian cancer cells (65).
In summary, studies in multiple human tumor model
systems, including malignant glioma, and carcinomas of the
lung, breast, prostate and ovary (26,37,38,40,58,61,62,65),
suggest that the therapeutic index of mda-7/IL-24 can be
enhanced by its use in combination with IR. The ability of
secreted mda-7/IL-24 to inhibit tumor angiogenesis, which
is promoted by IR, provides another reason for using this
combinatorial approach for cancer therapy. Of additional
importance, the ability of the combination of mda-7/IL-24 and
IR to reverse resistance in specific cancers, such as prostate
carcinoma cells overexpressing Bcl-2 or Bcl-xL, to either
agent used alone, suggests expanded applications of this
novel cytokine in the context of potentially resistant tumor
cells. Further studies are necessary to confirm improved
antitumor activity in patients by combining mda-7/IL-24
with IR.
4. Ectopic expression of mda-7/IL-24 inhibits invasion
and migration of cancer cells
Abnormalities in smooth muscle cell (SMC) proliferation and
differentiation underlie the pathogenesis of proliferative
vascular diseases. Due to mda-7/IL-24's involvement in
apoptosis and differentiation processes in diverse cancers,
this gene was used to modulate SMC growth and migration
(75). Overexpression of mda-7/IL-24 suppressed growth of
PAC1 rat cells (exhibiting multiple chromosomal aberrations)
and induced apoptosis in this cell line in a dose-dependent
manner; this treatment had no effect on normal primary
human coronary artery cells or rat aortic SMC despite the
high levels of MDA-7/IL-24 expression in all SMC. Ad.mda-7
also inhibited serum-stimulated PAC1 cell migration. In
contrast, recombinant MDA-7/IL-24 protein did not elicit
death or STAT3 activation in PAC1 cells that lacked IL-20/
IL-22 receptors suggesting that the effects of Ad.mda-7 were
mediated through intracellular pathways.
When applied to human non-small cell lung carcinoma
cells (NSCLC), Ad.mda-7 inhibited migration and invasion
of H1299 and A549 cells (76). Mechanistic studies revealed
down-regulation of PI3K/PKB, FAK and MMP-2 and -9
following Ad.mda-7 infection. Furthermore, tumor cells treated
with Ad.mda-7 ex vivo or with DOTAP:Chol-mda-7/IL-24
complex in vivo formed significantly less tumors in an experi-
mental lung metastasis model. Both migration and invasion
processes played pivotal roles in cancer metastasis. Thus,
MDA-7/IL-24-based drugs may provide a novel therapeutic
strategy that can inhibit tumor growth directly by inducing
apoptosis, and may also prevent tumor invasion, ultimately
reducing metastasis.
Sauane et al (45) compared the effect of secreted and
non-secreted forms of MDA-7/IL-24 on C8161 tumor cell
invasiveness. The C8161 cell line is characterized by very high
invasive capacity in vitro and by tumorigenic and metastatic
properties in vivo in nude mice (77). Infection of C8161 cells
with Ad.SP-mda-7 (an adenovirus producing a version of
mda-7/IL-24 that is not secreted because of the absence of
the secretory signal peptide at amino acids 1-49) or with
Ad.mda-7 inhibited to a similar extent the ability of these
cells to invade through Matrigel-coated membrane inserts as
compared with Ad.vec infected cells. In these experimental
settings, no effect was observed on C8161 cell growth in
monolayer, thereby confirming that invasiveness was not
inhibited because of loss of cell viability (45).
Moreover, MDA-7/IL-24 secretion by normal cells inhibited
invasion of cancer cells expressing the complete set of IL-20/
IL-22 receptors, such as DU-145 or BxPC-3, but not A549 cells
that lack a full complement of IL-20/IL-22 receptors (35). In
these experiments, P69 immortalized normal human prostate
epithelial cells were infected with Ad.mda-7 and cocultivated
with different cancer cells for 48 h and then evaluated for
invasion. Under these conditions, no decrease in cell growth or
viability was evident, and no apoptosis was induced in these
cancer cells (35). These results indicate ‘antitumor (invasion
inhibition) bystander effect’ of secreted MDA-7/IL-24 protein
can be expected to enhance the therapeutic properties of this
cytokine and promote biologically relevant effects at a distance
from its initial cellular site of synthesis and secretion.
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5. Antiangiogenic activity of mda-7/IL-24
Angiogenesis, a complex process that involves many cell
types and a finely orchestrated series of events that include
endothelial cell proliferation, new capillary formation,
attraction of pericytes and macrophages, disruption of existing
extracellular matrix and deposition of new matrix, is a critical
process required by solid tumors to support their growth
(78,79). The role of angiogenesis in growth and metastasis of
tumors is well established and recent studies support the
concept that metastasis from solid tumors is facilitated by
angiogenesis of the primary tumor (80). In these contexts,
inhibition of tumor angiogenesis should prove to be an effective
means of inhibiting cancer growth and spread.
A number of angiogenesis inhibitors have been identified
and found to block tumor growth by inhibiting tumor angio-
genesis in preclinical studies (81-91). Angiogenesis may be
regulated on multiple levels: some inhibitors may function to
impede the formation of new blood vessels (antiangiogenic),
whereas others may disrupt or modify existing vessels (anti-
vascular). Although several antiangiogenic molecules have
been developed and tested only a few have demonstrated a
therapeutic effect in clinical trials (81,82). Based on the
potential relevance of this approach and its limited current
success, there has been a need to identify and characterize
new and novel agents that target the tumor and its vasculature.
Below, we summarize preclinical findings showing the anti-
angiogenic activity of mda-7/IL-24.
Initial studies testing the antitumor activity of mda-7/IL-24
using an adenoviral vector (Ad.mda-7) demonstrated that
Ad.mda-7 was cytotoxic to a panel of human lung tumor cells,
but not to endothelial cells in vitro (24). However, in vivo
molecular analysis of the growth inhibitory effects showed
Ad.mda-7-treated tumors had reduced tumor vascularization
compared to control vector-treated tumors (24). These results
suggested that the reduced tumor vascularization in Ad.mda-7-
treated tumors could be either due to direct tumor killing or
antiangiogenic activity. To test whether mda-7-mediated an
antiangiogenic activity, in vitro and in vivo experiments were
conducted. In in vitro studies, Ad.mda-7-treated human H1299
lung tumor cells that served as an ectopic source for MDA-7/
IL-24 protein were mixed with human umbilical vein
endothelial cells (HUVEC) and plated onto Matrigel coated
96-well plates and observed for endothelial cell differen-
tiation (ECD), an assay that is routinely used to test for anti-
angiogenic activity. Tumor cells that were treated with PBS
or infected with Ad.luc (vector control) and mixed with
HUVEC served as controls. A marked inhibition of ECD was
observed in wells containing Ad.mda-7-treated tumor cells
(Fig. 3). No inhibition of ECD was observed in wells that
contained PBS or Ad.luc-treated tumor cells. These results
showed that tumor cells exogenously expressing MDA-7/IL-24
protein when in close proximity to endothelial cells could
inhibit ECD. These observations confirm that mda-7/IL-24
has antiangiogenic activity.
Although results from in vitro mixing experiments
supported in vivo findings for mda-7/IL-24-mediated anti-
angiogenic activity, the exact mechanism was not known.
Furthermore, previous studies had shown that tumor angio-
genesis could be inhibited directly by suppressing tumor blood
vessel formation and indirectly by suppressing the production
of tumor-derived growth factors, such as vascular endothelial
growth factor (VEGF), fibroblast growth factor (FGF) and
interleukin-8 (IL-8) (78-81). Thus, it was possible that mda-7/
IL-24 exerted its antiangiogenic activity by a direct or an
indirect mechanism or by a combination of both processes.
Confirmation of direct and indirect inhibitory effects of mda-7/
IL-24 on tumor angiogenesis is discussed below.
Direct inhibitory effect. To test whether mda-7/IL-24 directly
affected the tumor vasculature, experiments were performed
using affinity purified human MDA-7/IL-24 protein (7). In vitro,
MDA-7/IL-24 protein selectively inhibited ECD with no
effect on cell proliferation (92). The inhibitory effect on ECD
was dose-dependent with complete inhibition occurring at
concentrations above 10 ng/ml. Note, at the concentrations of
MDA-7/IL-24 protein used no significant cytotoxicity against
receptor-negative lung tumor cells was observed indicating
selective activity against receptor-positive endothelial cells.
That the inhibitory effect was specific to MDA-7/IL-24
protein was demonstrated by immunodepletion studies (92).
Additionally, the inhibitory effect of MDA-7/IL-24 protein
on ECD was 10-50 times more potent than endostatin,
interferon-γ and interferon-inducible protein-10 when tested
at equimolar concentrations in vitro (92). Additional studies
showed that MDA-7/IL-24 protein effectively inhibited in a
dose-dependent manner VEGF and FGF-induced endothelial
cell migration (92). These results demonstrate direct anti-
angiogenic activities for the MDA-7/IL-24 protein.
Molecular analysis of MDA-7/IL-24 protein-mediated
antiangiogenic activity showed a requirement for IL-22R1,
one of the two receptors for MDA-7/IL-24 (32,33,92). The
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Figure 3. Demonstration of mda-7/IL-24-mediated antiangiogenic activity by tumor-endothelial cell mixing experiment in vitro. A, Human lung tumor cells
(H1299) treated with PBS, Ad.luc or Ad.mda-7 were plated in 96-well plates and overlayed with Matrigel. HUVEC seeded on top of the Matrigel were
analyzed for ECD or tube-formation. Significant inhibition of ECD was observed in wells that contained Ad.mda-7 treated tumor cells compared to PBS or
Ad.luc treated tumor cells. B, Photomicrograph showing H1299 cells at the bottom of the Matrigel coated wells.
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involvement of IL-22R for MDA-7/IL-24 protein-mediated
antiangiogenic activity was demonstrated by activation of
STAT-3 in HUVEC as a measure of receptor-ligand interaction
and by receptor-blocking studies (92). Although involvement
of IL-22R in MDA-7/IL-24 protein-mediated antiangiogenic
activity has been demonstrated, the role of the IL-20 receptor
in mda-7/IL-24-mediated antiangiogenic activity has yet to
be determined. Additionally, the downstream signaling
mechanisms regulated by mda-7/IL-24 in endothelial cells has
not been studied. One possibility is the activation of STAT-1,
a molecule that is associated with antiangiogenic phenotype
(93). Another possibility is mda-7/IL-24-mediated inhibition
of the PI3K/AKT pathway that is associated with a proangio-
genic phenotype. Recent studies have demonstrated PI3K/
AKT inhibition in Ad.mda-7-treated lung and breast cancer
cells (63,94).
Evidence for direct effects of MDA-7/IL-24-mediated anti-
angiogenic activity in vivo has been obtained. Subcutaneous
implantation of MDA-7/IL-24 producing 293 cells (293-
mda-7) mixed with receptor negative A549 lung tumor cells
(1:1 ratio) in nude mice demonstrated suppression of tumor
growth compared to tumor growth in mice implanted with a
mixture of parental 293 cells and tumor cells [Fig. 4; (92)].
Tumor growth inhibition was accompanied by apoptosis of
tumor endothelial cells and tumor cells, reduced hemoglobin
content, and less CD31 positive endothelial cells (92). These
results demonstrate the direct antiangiogenic activity of
MDA-7/IL-24 protein.
To test whether MDA-7/IL-24 protein can inhibit tumor
growth at a distant site systemically, A549 lung tumor xeno-
grafts were established subcutaneously in the lower right flank
of nude mice. Subsequently when the tumors had grown to a
size of 50-100 mm3, Matrigel containing parental 293 cells
or Matrigel containing 293-mda-7 cells were implanted
subcutaneously into the upper right flank of tumor-bearing
animals and the effects of mda-7/IL-24 on tumor growth were
measured. A significant growth inhibition with 40-50%
reduction in tumor size was observed in mice that were
implanted with Matrigel containing 293-mda-7 cells
compared to mice that were implanted with Matrigel containing
293 cells (92) (Fig. 5). That the observed tumor growth
inhibition was due to systemic inhibitory effects of MDA-7/
IL-24 protein on tumor angiogenesis was demonstrated by
detecting the protein in the blood and a reduction in CD31
positive blood vessels (92). Furthermore, no gross patho-
logical changes were observed in the animals implanted with
293-mda-7 cells suggesting that the protein had no toxic
side effects. These results demonstrated MDA-7/IL-24 protein
systemically inhibits tumor growth by inhibiting tumor
angiogenesis. Although demonstration of the antiangiogenic
activity of mda-7/IL-24 is exciting, it should be noted that
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Figure 4. Antiangiogenic activity of mda-7/IL-24 in vivo. Human A549 lung
tumor cells were mixed with parental 293 cells (A549 + 293) or mixed with
293-mda-7 cells (A549 + 293-mda-7) and implanted subcutaneously into the
lower right flank of nude mice. Tumor growth was measured at regular
intervals and experiments terminated after 3 weeks. A significant inhibition
of tumor growth was observed in mice implanted with a mixture of A549 +
293-mda-7 cells (bottom) compared to mice implanted with a mixture of
A549 + 293 (top).
Figure 5. Systemic inhibition of tumor vascularization by mda-7/IL-24. Sub-
cutaneous A549 lung tumor xenografts were established in nude mice in the
lower right flank. When the tumors were measurable, Matrigel encapsulated
293 or 293-mda-7 cells were implanted in the upper right flank. At 3-4 weeks
after initiation of the experiment animals were euthanized, tumors harvested
and tissue sections prepared, and stained for CD31 using FITC-conjugated
antimouse CD31 antibody. A significant decrease in CD31 positive blood
vessels was observed in tumors that were obtained from mice implanted
with 293-mda-7 cells compared to tumors that were obtained from mice
implanted with 293 cells.
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these studies were conducted in an immunodeficient nude
mouse model. It is of interest to test the systemic effects of
mda-7/IL-24 on tumor angiogenesis in an immunocompetent
mouse model as well as to evaluate for toxicity.
Intratumoral or systemic administration of mda-7-nano-
particles into immunocompetent C3H mice bearing syngeneic
UV2237m subcutaneous tumors or experimental lung meta-
stases resulted in tumor growth inhibition (20,76). Associated
with growth inhibition was the demonstration of reduced
vascularization demonstrating mda-7/IL-24-mediated anti-
angiogenic activity. Additionally, no measurable toxicity was
observed. The results from this study showed that the anti-
tumor activity of mda-7/IL-24 in immunocompetent tumor-
bearing mice is partly mediated by inhibiting angiogenesis
with no toxicity, a phenomenon akin to that seen in immuno-
deficient tumor-bearing mice.
Indirect inhibitory effect. Although direct antiangiogenic
activity for MDA-7/IL-24 protein was demonstrated (92),
MDA-7/IL-24 like many other antiangiogenic agents can also
indirectly exert its antiangiogenic activity by inhibiting tumor-
derived growth factor (IL-8, bFGF, VEGF) expression (95-97).
Thus, inhibition of these growth factors will result in the
suppression of tumor growth due to its inability to support
neovascularization. Supporting this possibility is the recent
report by Nishikawa et al (23) who showed inhibition of
VEGF, bFGF, and IL-8 in Ad.mda-7-treated human lung tumor
xenografts. In the same study, combining radiation therapy
with Ad.mda-7 documented enhanced radiosensitization of
lung tumor xenografts that was associated with a significant
inhibition of VEGF, bFGF, IL-8 and tumor neovascularization.
In fact, combination therapy showed greater inhibition of these
proangiogenic factors compared to radiation or Ad.mda-7
treatment alone. Thus, a role for indirect antiangiogenic activity
for mda-7/IL-24 was established. However, the molecular
mechanism by which mda-7/IL-24 exerted its inhibitory
activity on these growth factors was neither examined nor
reported.
Recent studies demonstrate that mda-7/IL-24 inhibits
VEGF expression at the transcriptional level resulting in
reduced VEGF protein expression [Fig. 6; (98)]. Molecular
analysis revealed that Src kinase regulated VEGF transcription
and protein expression and that mda-7/IL-24 directly inhibited
Src kinase activity, thereby resulting in reduced VEGF trans-
cription and expression. Additionally, tissue culture super-
natant collected from mda-7/IL-24-treated tumor cells that
contained reduced VEGF, as determined by ELISA, when
added to actively growing endothelial cells showed reduced
VEGFR2 signaling and Akt activation leading to inhibition
of cell proliferation and induction of apoptosis (98). In
contrast, addition of culture supernatants from tumor cells
that were treated with PBS or Ad.luc (vector control) and
contained high levels of VEGF resulted in increased endothelial
cell proliferation that was associated with increased VEGFR2
and Akt activation. Thus, mda-7/IL-24-mediated inhibition
of VEGF expression in tumor cells results in the inability of
the tumor to support endothelial cell survival. These results
showed that mda-7/IL-24 could inhibit angiogenesis indirectly
by inhibiting tumor-derived growth factor expression, such
as VEGF. Additional growth factors that were inhibited by
mda-7/IL-24 include IL-8, FGF, and TGF-ß (Inoue et al,
unpublished data). In conclusion, mda-7/IL-24 exerts its anti-
angiogenic activity both by direct and indirect mechanisms
that are mediated by the extracellular and intracellular protein,
respectively.
6. Immune properties of mda-7/IL-24
Several features of mda-7/IL-24 characterize this gene as a
cytokine and a member of the IL-10 family of cytokines. These
features include chromosomal location on chromosome
1q31-32 in a region containing a cluster of IL-10 family
member genes (3,5), translational regulation (42,44,99-101),
a secretory motif, and an IL-10 signature motif. Several experi-
mental studies document that MDA-7/IL-24 protein can be
secreted and that purified MDA-7/IL-24 protein can bind to
IL-20R1/IL-20R2 and IL-20R1/IL-22 receptor complexes
and activate STAT-signaling pathways (7,12,34,35). Physio-
logical expression of the mda-7/IL-24 gene occurs in a highly
restricted manner in human cells, and associates with cells
having immunological functions (5,7). Several studies show
expression of mda-7/IL-24 both on an mRNA and protein
level in melanocytes and a progressive loss of expression in
melanoma (2,5,10-13). Loss of mda-7/IL-24 expression in
progressing melanoma might contribute to the ineffective
immune response to melanoma (102).
Earlier studies based on multiple tissue Northern blots
containing poly(A) RNAs from normal human tissue demon-
strated mda-7/IL-24 tissue specific expression in thymus,
spleen and peripheral blood mononuclear cells (PBMCs)
compared to several other tissues (5). Two broad classes of
cells were shown to endogenously express mda-7/IL-24,
including melanocytes and subpopulations of PBMCs. These
included normal unstimulated or LPS stimulated monocytes,
anti-CD3 stimulated T-cells, and normal human melanocytes
(5,7,9).
A potential role for mda-7/IL-24 as a cytokine and its
involvement in the immune system has been highlighted in
two studies (7,9). Mda-7/IL-24 expression could be induced
in PBMCs upon treatment with LPS or PHA (7). In addition,
mda-7/IL-24 mRNA could be detected by real-time PCR in
monocytes and its expression was up-regulated in monocytes
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Figure 6. Inhibition of VEGF by mda-7/IL-24. Human prostate tumor cells
(LNCaP and DU-145) seeded in 6-well tissue culture plates were treated
with PBS, Ad.luc or Ad.mda-7. At 72-h after treatment, cells were harvested,
cell lysate prepared and subjected to Western blotting for VEGF protein
expression. Inhibition of VEGF that correlated with MDA-7/IL-24 protein
expression was observed in Ad.mda-7-treated tumor cells and not in PBS- or
Ad.luc-treated cells. VEGF was inhibited in both LNCaP and DU-145 tumor
cells. ß-actin was used as a loading control.
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by treatment with LPS or in T-cells, especially in CD4+ naïve
and memory cells, following activation by anti-CD3 mAb
(9). No expression has been shown in NK or B-cells before
or after stimulation. Further studies in T-cells demonstrated
that at earlier time points (6 h), mda-7/IL-24 expression
was down-regulated in cells undergoing T1 differentiation
(mediating cellular immunity) and slightly up-regulated in cells
undergoing T2 differentiation (regulating humoral immunity).
At 66 h, the expression increased in cells committed to T1
differentiation (9). However, the expression pattern in mouse
T cells is different from that in humans. The mouse counter-
part of mda-7, FISP, was shown to have exclusive expression
in Th2 lymphocytes (103).
Treatment of PBMCs with MDA-7/IL-24 protein, purified
from conditioned media of a 293-cell line stably expressing
mda-7/IL-24, resulted in the induction of IL-6, IFN-γ, TNF-α,
IL-1ß, IL-12, and GM-CSF (granulocyte macrophage-colony
stimulating factor) (7). These inductions were blocked, either
completely or partially, by simultaneous administration of
IL-10, which might occur due to sharing of receptor subunits
by IL-10 family and due to a 10-fold higher affinity of IL-10
for its receptors (9). However, treatment with MDA-7/IL-24
did not modulate the proliferative functions of PBMCs (7). It
was hypothesized that the secondary cytokines induced by
MDA-7/IL-24 might activate antigen presenting cells to present
tumor antigen, thereby triggering an antitumor immune
response (7). In PBMC cultures, the cytokine activity of
MDA-7/IL-24 was antagonized by the prototypic immuno-
suppressive cytokine IL-10. These results suggest that even
though MDA-7/IL-24 and IL-10 are related family members
and share 19% amino acid homology, they bind to different
receptors and appear to have opposing roles in regulating
immunity against incipient tumors. In melanoma, pathologic
progression correlates with increased IL-10 levels (104),
therefore IL-10 can function as an autocrine growth factor for
melanoma. Expression of IL-10 in melanoma and other tumors
may facilitate loss of immune surveillance by blocking tumor
antigen presentation and thereby inhibiting cell-mediated
immunity (9). In contrast, MDA-7/IL-24 induces cell cycle
arrest and death in melanoma cells, therefore mda-7/IL-24-
based drugs may be especially efficient for melanoma treatment
because they restore a protein involved in the genesis and
progression of this disease.
Garn et al (105) demonstrated expression of mda-7/IL-24
in response to stimulation by various members of the IL-10
family of cytokines in mouse and human macrophages. LPS
or IL-4 (but not TNF-α) treatment of rat alveolar macro-
phages resulted in mda-7/IL-24 mRNA and protein expression.
Induction of mda-7/IL-24 mRNA correlated with expression of
IL-1, IL-6, and TNF-α in cultured human monocytes infected
with influenza virus confirming a proinflammatory role for
this molecule.
More recent studies of mda-7/IL-24 induction in human
PBMCs stimulated by PHA and LPS or by allogeneic major
histocompatibility complex confirmed data presented by
Caudell et al (7), Wolk et al (9), and Garn et al (105) and
demonstrated that the expression of mda-7/IL-24 in human
PBMCs results from cytokine stimulation and is regulated at
the post-transcriptional level through stabilization of mda-7/
IL-24 mRNA (106). Individual cytokines including IL-2, IL-7,
IL-15, TNF-α, GM-CSF and IL-1ß stimulate the expression
of mda-7/IL-24 mRNA and protein, whereas interferons and
Th2 type cytokines fail to induce substantial mda-7/IL-24.
Since cytokines stimulating mda-7/IL-24 production were
secreted from cells involved in an inflammatory response,
the authors hypothesized that mda-7/IL-24 might play an
important role in the inflammatory response in the skin
occurring as a result of a danger signal initiated by viral or
bacterial infection or tumor cell growth. Even though MDA-7/
IL-24 protein induced inflammatory cytokines and activates
inflammatory and apoptotic signaling proteins, it did not
activate NF-κB alone, but significantly enhanced TNF-α-
induced NF-κB activation and NF-κB-regulated expression
of cyclin D1 and COX-2 (107). Potentiation of TNF-α-induced
NF-κB activation by MDA-7/IL-24 may occur through
MDA-7/IL-24-induced PKR activation, since it is known that
PKR activates NF-κB by phosphorylation of IκBα (108) or
by interacting with IKK (109,110). The effects described by
Aggarwal et al (107) appear to be receptor-independent.
In addition to direct tumor cell killing of transformed
human and rodent cells (14,17,18), mda-7/IL-24 gene transfer
can also elicit immunotherapeutic activity against syngeneic
murine melanoma tumors (111). UV2237m murine fibro-
sarcoma cells infected with Ad.mda-7 were not able to grow
after injection into syngeneic immunocompetent C3H mice,
in contrast with immunocompromised nude mice, in which
all mice developed tumors after the injection. The authors of
this study hypothesized that Ad.mda-7 treatment of tumors
would result in local MDA-7/IL-24 protein secretion, which
would induce or promote systemic antitumor immunity. As
predicted, when challenged with parental tumor cells, these
tumor-free C3H mice that previously received Ad.mda-7/IL-24
treatment experienced no tumor growth. Splenocytes prepared
from vaccinated C3H mice demonstrated higher proliferative
activity and produced elevated levels of TH1 cytokines, such as
TNF-α, GM-CSF, IL-6 and IFN-γ. These findings corroborate
the in vitro data of Caudell et al (7), which showed induction
of TH1 cytokines in human PBMCs following treatment with
purified human MDA-7/IL-24 protein. Production of IFN-γ,
TNF-α and IL-6 was also reported in the serum of patients
treated intratumorally with Ad.mda-7/IL-24 (27). An in vitro
subset analysis of splenocytes from vaccinated mice demon-
strated a significant increase in the CD3+CD8+ but not the
CD3+CD4+ cell population. These data are also in agreement
with the results from a recently finished clinical trial where
patients that received an intratumoral injection of Ad.mda-7
(INGN 241) experienced a marked increase in CD3+CD8+
T-cells after treatment (27). The exact mechanism of mda-7/
IL-24-induced systemic immunity is still unknown. One
possibility is that antigen-presenting cells take up for presen-
tation T-cell immunogenic apoptotic bodies resulting from
mda-7/IL-24-mediated apoptosis. Another possibility considers
activation of immune accessory and effector cells present
within the tumor microenvironment and at distant sites by
secreted MDA-7/IL-24 protein (111).
7. ‘Bystander antitumor’ activity of mda-7/IL-24
Multiple experiments performed in vitro and in vivo confirm
the remarkable ability of mda-7/IL-24 to induce apoptosis in
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most cancers. However, pancreatic cancer cells display an
inherent resistance to the adenovirus-mediated mda-7 infection
(44). Pancreatic cancer is a complex disease where multiple
subsets of genes undergo genetic changes during tumor
development and progression. One of the most frequent and
earliest genetic alterations in pancreatic cancer (85-95%)
involves activation of the K-ras oncogene (112). The lack of
activity of Ad.mda-7 is not a consequence of failure to express
mda-7/IL-24 mRNA. Rather, it involves a translational sup-
pression in conversion of this mRNA into protein (42,44,99).
When expression of mut K-ras is down-regulated by means of
antisense oligonucleotides, plasmid or adenovirus expressing
antisense K-ras, pancreatic cancer cells with mut K-ras
become sensitive to Ad.mda-7-induced apoptosis (44). This
observation itself provides a basis for developing rational
targeted therapies for pancreatic cancer. Furthermore, these
original studies using antisense phoshorothioate oligo-
nucleotides or DNA plasmid transfection to down-regulate
K-ras lead to another important and provocative observation
of ‘bystander antitumor’ activity in vitro and in vivo. Tumor
formation was suppressed when Ad.mda-7-infected cells
(estimated to be ~100% of the cells) were combined with
transfection with an antisense K-ras plasmid (likely transducing
~3-5% of the cells). Nevertheless, the growth of the whole
population of tumor cells was efficiently suppressed, a
phenomenon also observed in the in vitro setting. This supports
a ‘bystander antitumor’ effect in which tumor cells receiving
both mda-7/IL-24 and antisense K-ras-induced changes,
likely resulting from the secretion of MDA-7/IL-24 protein,
that led to cell death in tumor cells with none or only one of
these two genetic manipulations. Additional early evidence
of ‘bystander antitumor’ effect derives from experiments where
primary rodent hepatocytes were infected with Ad.mda-7
resulting in the production and secretion of bioactive MDA-7/
IL-24, which when applied to DU-145 cells suppressed their
growth in vitro (Su et al, unpublished data). Understanding
the mechanism underlying this ‘bystander antitumor’ effect
could provide new therapeutic insights as well as help in
defining ways of improving the anticancer properties of mda-7/
IL-24 (14).
Evidence for ‘bystander antitumor’ activity was recently
provided in vivo in human tumor xenograft nude mouse
animal studies (73). A conditionally replication competent
adenovirus (CRCA) was produced in which replication (E1A
function) was controlled by the cancer-specific promoter
derived from the PEG-3 gene (71,113) to drive replication in
tumor cells and mda-7/IL-24 expression was controlled by
the cytomegalovirus promoter in the E3 region of the adeno-
virus, Ad.PEG-E1A-mda-7 (73). Human breast carcinoma
cells were inoculated into the right and left flanks of athymic
nude mice producing tumors at both sites. Tumors that formed
in the left side of the animal were injected with Ad.PEG-
E1A-mda-7 resulting in eradication of this tumor (reflective
of a primary tumor) as well as elimination of the tumor on
the right side of the animal (reflective of a metastatic state).
Additionally, injection with a non-replicating Ad.mda-7 into
the left tumor resulted in tumor regression and a statistically
significant decrease, although not a complete eradication,
was also evident in the right tumor, confirming ‘bystander
antitumor’ activity of the secreted MDA-7/IL-24. The potent
inhibitory effects on distant tumors could be explained by a
direct action of the secreted cytokine following interaction
with its cognate IL-20/IL-22 receptors that activate signal
transduction pathways mediating antitumor activity (34,35).
Alternatively, the potent ‘bystander antitumor’ effect of
MDA-7/IL-24 on distant tumor cells may include stimulation
of NK cells, since athymic nude mice used in the experiments
still have a spleen and a liver and display potent NK cells
activity (114).
Three recent studies investigated the mechanism(s) of the
‘antitumor bystander’ effect exerted by MDA-7/IL-24 (34,35,
115). Transduction of both tumor and normal cells with Ad.
mda-7 gene results in secretion of glycosylated MDA-7/IL-24
protein (reviewed in refs. 4,14-16,18). While Ad.mda-7 and
GST-MDA-7 recombinant protein were able to selectively
kill cancer cells in a receptor-independent manner involving
both a secretory and non-secretory mode of action (45,53),
the ability of secreted MDA-7/IL-24 to suppress tumor cell
growth, inhibit invasion and radiosensitize cancer cells appears
to be receptor-dependent. As a cytokine belonging to the IL-10
family, secreted MDA-7/IL-24 protein can bind to two distinct
type II cytokine heterodimeric receptor complexes, type 1
IL-20R (IL-20R1/IL-20R2), and type 2 IL-20R (IL-22R1/
IL-20R2) (32,33). Ligand-mediated assembly of both receptor
chains rapidly activates STAT3 and, to a lesser extent, STAT1
(30). In melanoma cells, both type 1 and type 2 IL-20R mediate
transient STAT3 activation by secreted MDA-7/IL-24 protein.
This activation is inhibited by >90% by anti-MDA-7/IL-24
neutralizing antibodies (34). Although MDA-7/IL-24 induces
STAT3 activation and cytotoxicity in melanoma cells, these
events are uncoupled. Moreover, even though all of the IL-10
family members tested elicited STAT3 activation in melanoma
cells, MDA-7/IL-24 was the only cytokine that produced cell
death. Using antibodies against type 1 IL20R and type 2 IL20R,
Chada et al (34) demonstrated, also that MDA-7/IL-24-induced
apoptosis in melanoma cells is mediated by type 1 IL-20R
receptor, even though engagement of both type of receptors
resulted in STAT3 activation. The authors hypothesized that
the downstream signaling between MDA-7/IL-24 and other
members of the IL-10 family differs or that MDA-7/IL-24
may use a co-receptor not utilized by other family members
to activate apoptosis signaling. In a similar study, Zheng et al
(115) demonstrated that apoptosis induced by exogenous
MDA-7/IL-24 protein in breast cancer cells is mediated through
IL-20R1/IL-20R2 heterodimeric receptor complex and is
independent of STAT3 phosphorylation. Coadministration of
the related cytokine IL-10 inhibited MDA-7/IL-24-induced
killing and MDA-7/IL-24-induced up-regulation of the tumor
suppressor proteins p53 and p27Kip1 (115).
Su et al (35) provided evidence of a ‘bystander antitumor’
effect of mda-7/IL-24 resulting from secretion of this cytokine
by normal cells. Normal cells were infected with Ad.mda-7
and directly co-cultured with cancer cells or co-cultured with
cancer cells that were separated by an agar overlay, providing
a diffusion model for testing for cytokine efficacy. Cell
viability and apoptosis (direct co-cultivation), anchorage
independent growth (agar diffusion), radiosensitivity (agar
diffusion) and invasion (direct co-cultivation) of cancer cells
in vitro were evaluated using appropriate assays. Primary and
immortalized normal cells (PFHA, FM-516SV and P69)
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were infected with Ad.mda-7 resulting in the production and
secretion of MDA-7/IL-24 protein, which modulated the
anchorage-independent growth, invasiveness, survival and
radiosensitivity of cancer cells that contained functional IL-20/
IL-22 receptors, but not cancer cells that lacked a complete
set of receptors. Moreover, the combination of radiation and
MDA-7/IL-24 secreted from normal cells evoked a ‘bystander
antitumor’ effect not only in cancer cells inherently radio-
sensitive or permissive for mda-7/IL-24 killing, but also in
tumor cells overexpressing the antiapoptotic proteins BCL-2
or BCL-xL and displaying resistance to either treatment alone
(35,40). Furthermore, since this effect can occur even in the
presence of small amounts of secreted MDA-7/IL-24 protein
(that are barely detectable by Western blotting using polyclonal
antibodies to MDA-7/IL-24), secretion of this cytokine from
normal cells should have a profound impact on tumor growth
and radiosensitization in vivo by directly affecting tumor cell
survival and by inhibiting angiogenesis. As described above,
the recent study by Su et al (35) highlights the significance of
normal cells as contributors to the potent antitumor activity
of MDA-7/IL-24. A novel application of this cytokine to
enhance its cancer therapeutic efficacy could exploit normal
cells as a repository for producing low levels of MDA-7/IL-24
protein to facilitate both localized and systemic cancer
therapies. If successful and non-toxic in vivo, constitutively
expressing low levels of mda-7/IL-24 would allow a maxi-
mization of benefit of this novel anticancer gene therapy,
potentially providing a means of preventing, in real-time, tumor
and metastasis development.
As described previously, another potential mechanism
underlying mda-7/IL-24-mediated ‘bystander antitumor’ effect,
including inhibition of cancer cell growth in distant tumors in
an in vivo context, might be activation of the immune system.
Mda-7/IL-24 expression is restricted to melanocytes and those
tissues associated with the immune system, such as spleen,
thymus, and PBMCs. Expression of this gene induced in
PBMCs with purified recombinant MDA-7/IL-24 protein
resulted in the induction of multiple potent immunomodulatory
agents such as IL-6, IFN-γ, TNF-α, IL-1ß, IL-12, and granulo-
cyte macrophage-colony stimulating factor (7,27). These
secondary cytokines induced by mda-7/IL-24 might activate
antigen-presenting cells to present tumor antigens, thereby
triggering an antitumor immune response. Studies in a phase I
clinical trial involving intratumoral injection of Ad.mda-7
(INGN 241) suggest that these in vitro effects are recapitulated
in the context of patients supporting the immune modulating
properties of this cytokine (27). Although current studies were
performed in athymic nude mice that are immunocompromised,
these mice still have a spleen and a liver and display potent
natural killer activity (74,114).
Another aspect of the ‘bystander antitumor’ activity of
mda-7/IL-24, also elaborated on previously, relates to its
potent antiangiogenic activity (24,92). This possibility is
exemplified by studies by Nishikawa et al (23) using A549
non-small cell lung carcinoma cells that lack a complete set
of IL-20/IL-22 receptors. Established tumors in animals were
injected with Ad.mda-7 and then exposed to radiation. Histo-
logical examination of tumors revealed a significant reduction
in angiogenic factors (bFGF, VEGF) and microvessel density
with enhanced apoptosis in tumors receiving the combination
of Ad.mda-7 and radiation. Analysis of clonogenic survival
of HUVECs, A549 and normal human lung fibroblasts pre-
treated with conditioned medium from 293 cells stably
expressing mda-7/IL-24 indicated sensitization of the HUVECs
to radiation without affecting A549 or normal human lung
fibroblasts. These results confirm that a significant enhance-
ment in killing of A549 tumor cells was observed that was a
consequence of secreted MDA-7/IL-24 that was inhibiting
HUVECs and tumor angiogenesis. These results suggest
increased antitumor activity of Ad.mda-7 when combined
with radiation in non-small cell lung carcinoma, as has also
been shown in malignant gliomas and prostate and breast
cancers (26,37,38,40,53,61).
A seminal proof of the ‘bystander antitumor’ effects of
mda-7/IL-24 derives from the recent phase I clinical trial
(27,28). Administration of Ad.mda-7 (INGN 241) intra-
tumorally in patients with advanced carcinomas and melanomas
resulted in apoptosis in tumor cells receiving the mda-7/IL-24
transgene as well as death in tumor cells not initially receiving
the virally-transduced gene. Immunohistochemical staining
demonstrated that ~30% of the tumor mass received the mda-7/
IL-24 gene, however, ~70% of the tumor cells showed
detectable apoptosis. This can reflect both a direct effect of
secreted MDA-7/IL-24 or an immune-mediated antitumor
response, or a combination of both processes.
The ability of a gene therapeutic to effectively manage
cancer is dependent upon a number of factors and technical
issues. Induction of direct tumor cell killing with the potential
to be transmitted in the circulation to elicit an effect not only
on a primary tumor, but also metastases, is a profoundly
important component required for an effective cancer gene
therapeutic. As highlighted in this review, mda-7/IL-24 not
only induced apoptosis selectively in cancer cells, but it also
has immune modulatory, radiation enhancing, antiangiogenic
properties and potent ‘bystander antitumor’ effects, thereby
making it an ideal candidate for promoting effective cancer
gene therapy (6,7,14,17,24,27,28,35,44,92). Because of these
essential qualities as a potential therapeutic gene for cancer, a
replication-incompetent adenovirus expressing mda-7/IL-24
(Ad.mda-7; INGN 241) was evaluated for safety in a phase I
clinical trial and based on these results (6,17,27-29), confirming
safety with a demonstrable clinical benefit, mda-7/IL-24 is
currently being evaluated for clinical efficacy in a phase II
clinical trial.
8. Translation of mda-7/IL-24 into the clinic - A good
beginning
Initial clinical testing of the mda-7/IL-24 gene as a cancer
therapeutic involved a non-replicating adenoviral (Ad) vector
deleted in the E1 region (INGN 241) as the delivery vehicle
(2,25). The initial trial was designed to prove the principle
of mechanistic activity of Ad.mda-7 and to demonstrate
tolerability. Preclinical models justified single-agent testing of
Ad.mda-7 (4,6,8,11-13,15-17,22,24,25,37,116). Combination
with chemotherapy, radiation therapy, and biological therapy
demonstrated no increase in toxic profile of mda-7/IL-24-
related adverse effects and suggested enhancement in immune-
related activity. Preclinical toxicology studies of Ad.mda-7 in
mice demonstrated adverse effects only at the highest dose
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[5x1012 viral particles (vp)/kg; equivalent to a human dose of
3x1014 vp], which consisted of decreases in body weight,
mild liver toxicity, and transient decreases in platelet count
(117,118). These results suggest that mda-7/IL-24 may be
optimally used therapeutically when combined with other
treatment modalities (6,14,17-19) and supported initiation of
clinical investigation. Thus far, however, clinical investigation
has been limited and focused on sorting out mechanistic,
pharmacodynamic, and pharmacokinetic issues using mono-
therapy. A single trial has been completed (28).
Safety. Twenty-two patients with refractory cancer and
accessible tissue for surgical biopsy were entered into the
first trial with Ad.mda-7 (Table I) (28). This was a dose
escalation study in which patients received 2x1010-2x1012 vp
delivered to the central region of the target tumor. Twenty-
two patients completed 1 complete cycle (30 days). Treatment
schedules ranged from a minimum of a single injection to
two injections per week for 3 weeks. Of the evaluable patients
there were 13 females and 9 males. Age ranged from 38 to 92
years, with a median age of 66 years. All patients had been
heavily pretreated. Malignant melanoma (21.4%), squamous
cell carcinoma of the head and neck (18%), breast carcinoma
(14%), and colorectal carcinoma (7%) were the most frequent
tumor types treated primarily due to accessibility of injectable
tumor lesions. Adverse events were generally mild; transient
fever being most common. There was one grade 3 serious
adverse event (SAE) involving fatigue in a high dose-treated
patient, which was thought possibly to be due to the study
drug. The most common mild adverse event specifically related
to injection of the study drug was included injection site pain.
These effects were seen more consistently at higher doses and
delivered volumes of Ad.mda-7 and they generally resolved
within 48 h after injection. In two patients in the highest dose
schedule cohort (twice-weekly injections), marked skin
erythema was noted surrounding the injected lesion within
24 h of the injection. This resolved over the next 96 h. A
maximum tolerated dose was not attained in this study as the
maximum monofacturable concentration was delivered.
Overall, Ad.mda-7 was well tolerated when administered in
single or multidose regimens.
Clinical response. In the first six patient cohorts, injected
tissue was excised within 24-96 h after injection. No clinical
activity was observed within 24-96 h, although minor changes
in morphology in the injected lesions were noted. Three
patients receiving the highest single-dose therapy via intra-
tumoral injection exhibited SD (stable disease), with 0, 0,
and 23% reduction in tumor size (melanoma, colorectal
carcinoma, and SCCHN, respectively). Off-study tumor
measurements were taken 5-7 weeks from screening. Time
from first injection to death for these patients was 347, 351,
and 401 days, respectively.
Eight patients in cohort 8 received injections twice weekly
for 3 weeks (in a 28-day cycle for 1 or more cycles); five
patients completed at least one cycle of treatment. All patients
in this cohort had failed multiple prior therapies (Table II). Two
of five patients demonstrated a clinically-significant response to
Ad.mda-7 injections consisting of at least partial regression of
the injected lesion. The most dramatic of these responses was
in a 64-year-old female with widely metastatic melanoma (at
study entry, she had >10 distinct lesion). Her initial site of
treatment was a superclavicular node measuring 2x2 cm at
baseline. No appreciable change was noted for the first five
injections but by the sixth (and final) injection, a clear decrease
in the size of the lesion was apparent and associated erythema
was evident. Regression continued over the next 2 weeks until
there was no clinical evidence of disease at that site (29)
(Fig. 7). Subsequently, a second course of injections was begun
on a lesion on the dorsum of her right hand. The baseline
measurement was 1.8x2.3 cm and regression was evident
by the fifth injection (84% reduction in lesion area). After
LEBEDEVA et al:  mda-7/IL-24, NOVEL ANTICANCER CYTOKINE998
Table I. Patient characteristics and dosing.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Cohort No. of patientsa Age (range) Previous treatmentsb Dose (vp) Adverse eventsc
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
1 1 (1) 49 S, C, Ca, N, H, G 2x1010 2
2 1 (1) 44 S, F, I 2x1011 1
3 3 (3) 74 (66-76) S, RT, T, P, C, V, D, Fl, Cl 2x1012 0/1/1
4 3 (3) 45 (38-60) S, A, C, T, Ta, N, P, RT, E 2x1012 0/1/0
5 4 (3) 75 (65-75) S, Ta, RT, I, D 2x1012 0/2/2
6 1 (1) 57 S, A, T, Ta 2x1012/divided doses 0
7 7 (5) 86 (76-92) S, M, V, A, P, T, G, RT, F, I 2x1012 2/0/0/2/2
8 8 (5) 64 (62-91) S, RT, IF, IT, P, T, F 2x1012 repeated 2x week 2/2/2/1/1d
for 3 weeks
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
aNo. of patients enrolled per cohort is indicated. The no. of patients completing at least one cycle of treatment is shown in parentheses.
bPrior treatments: S, surgery; A, adriamycin; C, cyclophosphamide; Ca, capecitabine; Cl, chlorambucil; D, dacarbazine; E, etoposide; F,
5-fluorouracil; Fl, fluradabine; G, gemcitabine; H, herceptin; I, irinotecan; IF, IFN-γ; IT, immunotherapy; M, methotrexate; N, navelbine;
P, platinum; RT, radiotherapy; T, taxane; Tz, tamoxifen; V, vincristine. cAdverse events possibly or probably related to INGN 241
administration are indicated (≤grade 3). dOne cohort 8 patient experienced a grade 3 SAE and withdrew from the study.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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completing six injections, the residual lesion was excised and
on microscopic examination it was found to have marked
inflammatory lymphoplasmacytic infiltrates throughout the
residual nodule and surrounding tissue. There was also
extensive coagulative necrosis in the tumor. A third lesion on
the anterior right thigh was next treated in the same patient
with two cycles of injections. Regression of this lesion was
also observed after the first course of injections (baseline
measurements 3.5x3.3 cm; 35% reduction), but a second set
of injections produced no further response. Interestingly,
several distant uninjected melanoma lesions also became
erythematous during the course of injection of the target
lesion, although clinical regression was not seen at these
distant sites. This patient, a 64-year-old woman, survived 773
days after initiation of treatment with Ad.mda-7. An additional
melanoma patient exhibited a partial response (33% decrease
by RECIST criteria). Five of the eight cohort 8 patients
survived more than 2 years, four are still alive at 1643, 1550,
1267, and 1261 days.
We saw a less dramatic response in another patient with
squamous cell carcinoma of the penis with multiple skin
nodules in the groin and right hip area. Injection of Ad.mda-7
into one of the upper right hip lesions (2.5x3.0 cm at baseline)
produced significant central necrosis with surrounding
erythema by the fifth injection. However, the lesion continued
to expand peripherally so that by completion of the first set
of six injections, there was an indurated rim of erythematous
tissue surrounding the central area and the total measurement
of the lesion was 3.0x4.0 cm by the end of the 6th injection.
A large central portion of the lesion (approximately two-
thirds of the total area) remained blackened and necrotic at
the end of cycle 1. Other, new lesions were rapidly appearing
in the region, so the patient was removed from the study as
PD, and he went on to other therapy. Three additional patients
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Table II. Responses in cohort 8 patients.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Patient Gender/age Diagnosis Date diagnosed Previous treatmentsa No. of injections Responseb Time to deathc
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
81 M/71 Adenocarcinoma 1998 P, T, G 2d SD nd
83 F/64 Melanoma 1994 S, RT, IT, IF 24e CR, PR, SD >600
84 F/62 Melanoma 2000 S, RT, IT, IF 12 PR 309
85 M/64 Penile carcinoma 2002 S, RT, CDDP, T 6 PD 75
86 F/66 NSCLC 2001 RT, P, T 3d SD 180
87 M/62 SCCHN 1992 S, RT, CDDP, T, F, P 6 PD 185
88 M/91 Lip carcinoma 1982 S, RT 6 SD 181
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
aPrior treatments: S, surgery; F, 5-fluorouracil; G, gemcitabine; IF, IFN-γ; IT, immunotherapy; P, platinum; RT, radiotherapy; T, taxane.
bSD, stable disease; CR, complete response; PR, partial response; PD, progressive disease. cTime in days from first injection of INGN 241
until death. dPatients 81 and 86 did not complete one full course of treatment (6 injections). ePatient received 12 injections on compassionate
use protocol.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Figure 7. Objective clinical response to INGN 241 (Ad.mda-7) in cohort 8 patient with metastatic melanoma (patient 83). Injected lesion was on right clavicle
(dashed circle in A). B, By day 4, region is inflamed. C, At the end of cycle 1 (day 30), lesion has completely regressed. This patient is still alive >600 days
after initiating treatment.
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(with adenocarcinoma, NSCLC, and lip carcinoma) exhibited
stable disease after Ad.mda-7 injection and one patient with
SCCHN exhibited disease progression (20% increase by
RECIST). Of the nine lesions treated in cohort 8 patients,
four demonstrated objective response (CR or PR by RECIST
criteria).
Gene expression. Gene transfer and biologic effects in resected
tumors were analyzed 1-4 days after injection. Quantitative
studies of vector-specific DNA and RNA at the point of
injection (center of lesion) and in serial sections to the
periphery of each lesion were performed. To facilitate
identification of the injection site, Isosulfan blue dye was
admixed with vector prior to administration. Thus, at resection,
the injection sites could be identified. All injected lesions
showed high levels of vector-specific DNA signals in tumors
(Fig. 8). Vector DNA, vector RNA, transgenic MDA-7/IL-24,
and TUNEL signals across the dose range of 2x1010-2x1012
vp were compared (Fig. 8). Although the sample size was
small, there was an indication of a dose-dependent increase
in the number of Ad.mda-7 vector DNA copies/μg DNA in
the tumor [7x107 copies/μg in the proximal (central) sections
of cohort 1 low dose compared to an average of 2.2x108
copies/μg] in the high dose cohort. A similar indication of
dose response for vector RNA was also observed, with 2.0x104
vector RNA copies found in the central section of tumors
injected with low dose INGN 241 (Ad.mda-7), whereas
2.3x107 copies/μg were observed in high-dose tumors (Fig. 8).
Note that the distal regions of tumors uniformly showed lower
vector signals than the proximal sections. Parallel sections
for transgenic MDA-7/IL-24 protein and apoptosis induction
via TUNEL assay were also evaluated. All patients demon-
strated undetectable MDA-7/IL-24 staining in the preinjected
baseline samples, whereas MDA-7/IL-24 immunostaining
was found in 20% of tumor cells from low dose, 30% of cells
at intermediate dose, and 53% of cells from tumors injected
with high dose of INGN 241. MDA-7/IL-24 staining in distal
regions of tumors after injection with low dose vector was
not observed, whereas up to 30% positive cells were found in
mid- and high-dose tumors. Apoptosis induction showed higher
trend with increased dose, except for the cohort 2, patient
(colorectal carcinoma), who exhibited unusually high TUNEL
reactivity of 75% after injection of Ad.mda-7 (Fig. 8B).
Dynamics of vector spread and subsequent gene expression
were also evaluated. The highest number of DNA vector
copies were found at the area of injection (e.g., the center of
injected lesions averaged greater than 1x108 vector DNA
copies/μg) and signal decreased significantly (p<0.02) with
distance from the injection site, vector DNA levels had fallen
by almost 90%. Low levels of vector DNA were detected up to
3-cm from the injection site; however, only 3 tumors showed
DNA signals greater than 1x106 copies/μg at 1-cm from the
injection site. Vector RNA levels were also quantitated and
they showed a pattern of distribution similar to that of the
vector DNA. Vector RNA was also distributed distally from
the injection site and, similar to vector DNA, vector RNA
signals were significantly reduced (p<0.05) with distance
from the injection site. Both vector DNA and RNA signals
showed exponential decay with distance from the injection
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Figure 8. Pharmacodynamics of INGN 241 vector and expression. A, Dose-
response of INGN 241 vector DNA and RNA. Tumor sections were obtained
from preinjected (pre), proximal and distal sections from cohort 1 to 3
patients and vector-specific signals evaluated by quantitative DNA- and RT-
PCR. RNA was not available from cohort 2 tumor. B, Dose-response of INGN
241 transgenic MDA-7/IL-24 expression and TUNEL reactivity. Tumor
sections were obtained from preinjected (pre), proximal and distal sections
from cohort 1 to 3 patients and vector-specific signals evaluated.
Figure 9. Intratumoral pharmacokinetics of vector DNA and mRNA. A,
Decay of INGN 241 vector at injection site. The median number of DNA
copies at each time point postinjection is shown; number of patients per
sample is indicated below. The number of DNA copies/Ag genomic DNA was
converted to illustrate the average number of vector DNA copies per cell -
shown above the graph. B, Decay of INGN 241 vector RNA at injection site.
The median number of RNA copies/Ag at each time point is shown; number
of patients per sample is indicated below.
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site. Regression analyses indicated very strong correlations
between vector DNA and RNA signals and distance from
injection site (correlation coefficient = 0.82-0.9).
The kinetics of vector DNA and transgenic mRNA were
evaluated for patients who received a single dose of INGN 241
(Ad.mda-7). Vector DNA reached maximum levels at the
point of injection 24-48 h after injection. If one assumes these
signals are cell-associated, then median signals approximated
1000 vector DNA copies per cell, a value 6 logs above pre-
injection controls (Fig. 9A). Vector-specific mRNA exhibited
a distribution and kinetic profile similar to that of vector
DNA (Fig. 9B). Median vector-specified RNA signals were
more than 4 logs greater in the center of injection lesions
compared to uninjected control samples (Figs. 8A and 9B).
Vector-specific RNA signals decreased by more than 2 logs
by day 4 (Fig. 9B). Samples were not available for day 30
analysis.
Transgenic gene expression. Tumors were excised and serially-
sectioned, then evaluated for transgenic MDA-7/IL-24 protein
expression and apoptosis. Pretreatment samples were uniformly
negative for MDA-7/IL-24 protein expression and most were
negative for TUNEL reactivity (average TUNEL signal was
<6% in cohorts 1-5). After Ad.mda-7 injection, all tumors
demonstrated substantial MDA-7/IL-24 immunostaining that
ranged from 20 to 90% positive tumor cells in the center of
the lesion. Transgenic MDA-7/IL-24 was detected beyond
the injection site: five of eight (62%) tumors had detectable
MDA-7/IL-24 at 1-cm from the single injection site, and
MDA-7/IL-24 expression was detected more than 3-cm from
the injection site. Up to 25% of MDA-7/IL-24 stained cells
were detected 16-mm from the point of injection. Reproducibly,
within each tumor, MDA-7/IL-24 immunostaining was reduced
with distance from the injection site. With the exception of
patient 2, ≥90% of MDA-7/IL-24 staining cells in all biopsies
exhibited malignant histological features. The remaining
MDA-7/IL-24-positive cells comprised infiltrating lymphocytes
and/or histocytic/reticuloendothelial cells.
Apoptosis staining varied, with up to 80% of tumor cells
at the center of the lesion demonstrating TUNEL reactivity.
Apoptosis declined with distance from the injection site; five
of seven (71%) tumors exhibited TUNEL reactivity beyond
1-cm from the injection site. Both MDA-7/IL-24 and TUNEL
staining demonstrated significant (p<0.02) linear decay with
distance from the injection site. Regions of tumor exhibiting
TUNEL staining strongly corresponded to those regions having
MDA-7/IL-24 protein expression; those samples with distal
MDA-7/IL-24 staining also showed distal TUNEL reactivity.
Both protein expression and apoptosis reactivity reached
maximum levels by 4-days postinjection but had returned to
baseline, preinjection levels by day 30 [(28) and data not
shown].
A representative example is shown in Fig. 10, which
illustrates the high level of MDA-7/IL-24 immunostaining
after Ad.mda-7 injection and the decay in protein, DNA, and
RNA signals with distance from the injection site. This patient
with a 5x5-cm SCCHN lesion was injected with 2x1012 vp
Ad.mda-7 and resected at 24 h. No MDA-7/IL-24 signal was
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Figure 10. Mda-7/IL-24 transgene expression correlates with distribution of vector throughout the tumor. One-half of the tumor was analyzed for MDA-7/IL-24
protein expression and the other half for vector-specific DNA and RNA levels. The number of DNA copies/μg genomic DNA and number of RNA copies/μg
total RNA is shown for each tumor section. TUNEL reactivity was 50% in the central section and 30% at the periphery section 3.
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observed in the pretreatment lesion, whereas the injection site
(center section) exhibited up to 75% of tumor cells staining
for MDA-7/IL-24. Staining intensity decreased with distance,
but the distal lesion (18-mm from injection site) still showed
regions of strong MDA-7/IL-24 staining (Fig. 10). Parallel
sections were evaluated for apoptosis. The central section
showed 50% TUNEL reactivity, whereas the distal section
showed 30% staining. The levels of vector-specific DNA
and RNA showed strong signals at the injection site, which
decreased markedly (more than 100-fold) at the periphery
(Fig. 10). Overall, vector-specific DNA and RNA, MDA-7/
IL-24 protein levels, and TUNEL reactivity demonstrated
similar dose response and kinetic and radial concentration
gradients, although MDA-7/IL-24 and TUNEL signals
persisted longer and showed enhanced distribution.
Conclusions from the phase I clinical trial. Direct injection of
an adenovirus containing the mda-7/IL-24 cDNA (INGN 241)
into a variety of solid tumors was generally well tolerated, with
injection site pain and erythema being noted locally in some
patients. One patient experienced a grade 3 SAE of fatigue
and was discontinued from the study.
Analysis of serial sections of injected lesions demonstrated
that mda-7/IL-24 DNA and RNA were detectable in 100% of
the injected lesions, with the highest concentrations found at
the site of injection, as expected. However, MDA-7/IL-24
protein was detectable in the periphery of injected lesions
(greater than 3-cm from injection site), beyond the area of
DNA spread, suggesting that the MDA-7/IL-24 protein can
diffuse from transduced cells, which supports the in vitro
‘bystander antitumor’ studies (18,35,44).
Apoptosis, as measured by TUNEL assay, was significant
in the injected lesions and also correlated geographically with
MDA-7/IL-24 protein expression. Both MDA-7/IL-24 trans-
genic protein expression and apoptosis decayed with similar
intratumoral dynamics. One hundred percent of injected
tumors evaluated in the phase I clinical study demonstrated
transgenic MDA-7/IL-24 expression and elevated apoptosis
induction compared to untreated control tumors. In contrast,
adenoviral-mediated gene transfer of p53 by injection into non-
small cell lung cancer tumors resulted in vector detection by
DNA PCR in 86% of patients' tumors and increased apoptosis
in 46% of biopsy specimens (119). Indeed, as most previous
gene transfer studies have not been structured to assess the
geographic extent of vector distribution and biological effect,
it is difficult to compare INGN 241's effects directly with
other studies. One report has indicated that administration of
Ad.p53 to glioma is hampered by the limited spread (<5 mm)
of transduced cells (120). Both INGN 241 DNA and transgenic
MDA-7/IL-24 protein distribute to a greater extent and demon-
strate strong correlations with distance from injection site
(p<0.02). Nucleic acid signals decay by 50% at 4-6-mm from
the injection site whereas MDA-7/IL-24 protein and apoptosis
signals decay by 50% at 18-20-mm. Therefore, either INGN
241 (Ad.mda-7) is more potent than other therapeutic
constructs at inducing apoptosis in human tumors or the study
design allowed us to capture signals that were lost in other
studies. The levels of apoptosis induction observed in this
study are substantially higher (average = 45%) than reported
with other anticancer drugs. Apoptosis induction correlates
with loss of Ki-67 staining (27). It is noteworthy that seven
different tumor types were treated in cohorts 1-6 and all
showed high levels of MDA-7/IL-24 expression and sub-
sequent apoptosis induction. As discussed above, all of these
patients had been heavily pretreated and failed multiple
treatment regimens. It would be predicted that this group of
chemo- and radio-resistant tumors would have acquired
resistance to apoptosis. The fact that MDA-7/IL-24 induces
apoptosis in such a spectrum of advanced tumor types mirrors
preclinical studies and suggests that INGN 241 (Ad.mda-7)
may have broad utility.
As discussed in other parts of this review, in addition to
apoptosis induction of tumor cells and immunostimulation,
additional ‘bystander antitumor’ activities have been reported
for MDA-7/IL-24. Ad.mda-7 was reported to inhibit endo-
thelial differentiation in vitro, implying antiangiogenic
activity (24). Further studies demonstrated antiangiogenic
activity of Ad.mda-7 in vivo (23), in that MDA-7/IL-24
expression significantly repressed angiogenic mediators,
including VEGF, basic FGF, and IL-8. Studies using purified
MDA-7/IL-24 demonstrated that it functions via the IL-22R1
on endothelial cells (92), and MDA-7/IL-24 was 50-fold
more active than endostatin or angiostatin. When Ad.mda-7
was combined with irradiation, synergistic inhibition of tumor
growth was observed, with significant reduction in microvessel
density and pronounced apoptotic response in the tumor (23).
Two recent preclinical studies have provided support for
intriguing observations about the role of MDA-7/IL-24 in
melanoma disease progression and metastasis. Initial studies
found that MDA-7/IL-24 mRNA and protein were expressed
in normal human melanocytes and benign nevi, but expression
was lost in metastatic melanoma (2,11). Subsequent studies
evaluated larger patient groups and concluded that MDA-7/
IL-24 protein expression is progressively lost as melanoma
tumors invade and become more metastatic and aggressive
(10). These authors speculated that MDA-7/IL-24 must play
a role in maintenance of normal physiology of melanocytes
and that inhibition of MDA-7/IL-24 results in transformation
and progression from a local, non-metastatic primary tumor
to a highly metastatic phenotype (2,10,11). Additional studies
have shown that Ad.mda-7 can inhibit cell migration and
invasion of lung and breast tumor cells by down-regulating the
PI3K pathway and inhibiting production of FAK and matrix
metalloprotease (63,94). Tumor cells expressing MDA-7/IL-24
demonstrated significantly reduced lung metastases compared
to control cells (76,94). It is clear that tumor cells can develop
resistance to cytotoxic therapies, and reports are now emerging
of acquisition of resistance to pathway-specific molecularly
targeted therapeutics. The antitumor effects mediated by
MDA-7/IL-24 encompass a variety of signaling pathways,
and it is anticipated that redundant proapoptotic signals are
activated (14). The ability of mda-7/IL-24 to enhance the
therapeutic activity of radiation, monoclonal antibody therapy
and chemotherapy provide additional avenues worth exploring
as a means of enhancing the therapeutic index of this novel
cytokine (5,6,14,16,18,26,35,37,38,40,42,58,61,62,65,68,
118,121).
Transient increases in circulating cytokines such as IL-6,
IL-10, and TNF-α in response to MDA-7/IL-24 were observed.
Significantly higher elevations of IL-6 and TNF-α were
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observed in patients receiving repeat treatment who demon-
strated evidence of activity related to Ad.mda-7 (27). The
majority of patients also showed a marked increase in CD3+
and CD8+ T cells at day 15 following injection, suggesting that
Ad.mda-7 may be associated with a TH1 response. Further-
more, MDA-7/IL-24 has been shown to inhibit G2/M cell
cycling (12,24,50). The effect of MDA-7/IL-24 on tumor
suppressor genes, such as ß-catenin and iNOS, was also
evaluated (27). ß-catenin expression was reduced in six of
nine patients and iNOS expression was reduced in four of
nine patients tested.
In summary, Ad.mda-7 can induce a wide variety of effects
associated with anticancer activity following intratumoral
injection. Clinically significant responses were primarily
seen with repeat injection. Future studies, therefore, will need
to concentrate on repeat dosing of Ad.mda-7, particularly in
malignant melanoma, in which the greatest clinical activity
was seen in the first phase I study (29). Other future directions
include developing systemic administration of Ad.mda-7, given
its widespread tumor selectivity, exploration of its immuno-
potentiating effects, and its use in combinatorial strategies.
9. Future applications for improving the therapeutic index
of mda-7/IL-24
In a remarkably short time frame, mda-7/IL-24 has gone from
a laboratory discovery into the clinic. The results achieved to
date using this gene are very encouraging and suggest that
mda-7/IL-24 will provide significant benefit as a therapeutic
for cancer. Although the results of the phase I clinical trial
are provocative, it is clear that approaches to enhance the
therapeutic benefit of mda-7/IL-24 are necessary to maximize
its effectiveness in patients. Several approaches to achieve
this objective were recently highlighted (14). One strategy,
which has already proven efficacious, is the application of
conditionally replication competent bipartite adenoviruses that
both replicate and express mda-7/IL-24 in tumor cells (73,122,
123). These novel viruses have shown enhanced effectiveness
in athymic nude mice containing human breast (73), colorectal
(122) or therapy-resistant prostate (123) tumors in comparison
with non-replicating adenoviruses expressing mda-7/IL-24.
Augmentation of the antitumor properties of mda-7/IL-24 has
also been achieved by using this gene in combination with
radiation, chemotherapy or monoclonal antibody therapy
(reviewed in refs. 18,19). Combining mda-7/IL-24 with agents
that promote ROS production has been shown to augment
therapeutic action of this gene in the context of prostate and
pancreatic carcinomas (42,43). In this context, agents that can
evoke this change in cancer cells may provide useful reagents
to enhance therapeutic activity of mda-7/IL-24. Additionally,
approaches that facilitate delivery of mda-7/IL-24 to the
tumor microenvironment and tumor cells, including the use
of stem cells and dendritic cells, offer promise for increasing
therapeutic index of this novel cytokine (14). Although
requiring further development and testing, modifying normal
cells to produce and secrete MDA-7/IL-24 protein could in
principle permit an even further expansion of clinical utility
for this interesting molecule (14,35). Additionally, using
agents that can induce MDA-7/IL-24 expression in cancer
cells, thereby resulting in apoptosis, represents a unique
therapy for cancer (124). Clearly, these and other approaches
will require further study to define ways of more effectively
using mda-7/IL-24 as a cancer gene therapeutic. We remain
cautiously optimistic relative to the use and effectiveness of
this novel cytokine for the therapy of diverse human malig-
nancies.
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